Practice Point®: Hematology

Episode 44 - Hematologic Cancer Updates | Key Advances in Leukemia, MDS and MF Podcast

21 min · 10 dec 2025
aflevering Episode 44 - Hematologic Cancer Updates | Key Advances in Leukemia, MDS and MF Podcast artwork

Beschrijving

Breakthroughs in hematologic cancers continue to emerge. Staying aligned with the newest insights from leading medical conferences is essential for healthcare providers committed to delivering cutting-edge care. Through impactful presentations, posters and abstracts, Dr. Raajit Rampal provides expert commentary on the latest advances in Leukemia, Myelodysplastic Syndromes (MDS) and Myelofibrosis (MF) presented at the annual hematology meeting in Orlando, FL. Launch/Release Date: December 10, 2025 Activity Expiration Date: November 30, 2026 FACULTY Raajit Rampal, MD, PhD Director, Myeloproliferative Neoplasms Program Director, Center for Hematologic Malignancies Memorial Sloan Kettering Cancer Center This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link [https://www.practicepointcme.com/CMEHome/hematologic-cancer-updates-key-advances-in-leukemia-mds-and-mf-podcast] prior to listening to this podcast.

Reacties

0

Wees de eerste die een reactie plaatst

Meld je nu aan en word lid van de Practice Point®: Hematology community!

Probeer gratis

Probeer 14 dagen gratis

€ 9,99 / maand na proefperiode. · Elk moment opzegbaar.

  • Podcasts die je alleen op Podimo hoort
  • 20 uur luisterboeken / maand
  • Gratis podcasts

Alle afleveringen

51 afleveringen

aflevering Episode 51 - Podcast: What I'd Do Differently Tomorrow - Part 5 of RRMM Podcasts: Practical Insights for the First Relapse artwork

Episode 51 - Podcast: What I'd Do Differently Tomorrow - Part 5 of RRMM Podcasts: Practical Insights for the First Relapse

Managing relapsed/refractory multiple myeloma (RRMM), particularly at first relapse, requires timely, evidence-based decisions in an increasingly complex treatment landscape. As therapeutic options continue to expand and clinical guidance evolves, healthcare professionals must navigate challenges related to risk stratification, treatment selection, sequencing strategies, and the integration of emerging immunotherapies into practice. Clinicians may also face uncertainty in distinguishing mechanisms of action, managing immune-related toxicities, and selecting appropriate therapies in the context of treatment resistance. Additionally, real-world barriers such as staffing shortages, infusion capacity constraints, and workflow demands can complicate the implementation of optimal care. This podcast series features expert-led conversations that deliver practical insights and real-world strategies to support confident, guideline-informed decision-making in the management of RRMM. Launch Date/Release: July 2, 2026 Expiration Date: August 31, 2027 FACULTY Ajai Chari, MD Professor of Clinical Medicine University of California, San Francisco Sagar Lonial, MD, FACP, FASCO Chair and Professor Department of Hematology and Medical Oncology Anne and Bernard Gray Family Chair in Cancer Chief Medical Officer Winship Caner Institute | Emory University This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link [https://www.practicepointcme.com/CMEHome/rrmm-podcasts-practical-insights-for-the-first-relapse] prior to listening to this podcast.

2 jul 20267 min
aflevering Episode 50 - Podcast: From Knowing to Doing: Overcoming Real-World Barriers - Part 4 of RRMM Podcasts: Practical Insights for the First Relapse artwork

Episode 50 - Podcast: From Knowing to Doing: Overcoming Real-World Barriers - Part 4 of RRMM Podcasts: Practical Insights for the First Relapse

Managing relapsed/refractory multiple myeloma (RRMM), particularly at first relapse, requires timely, evidence-based decisions in an increasingly complex treatment landscape. As therapeutic options continue to expand and clinical guidance evolves, healthcare professionals must navigate challenges related to risk stratification, treatment selection, sequencing strategies, and the integration of emerging immunotherapies into practice. Clinicians may also face uncertainty in distinguishing mechanisms of action, managing immune-related toxicities, and selecting appropriate therapies in the context of treatment resistance. Additionally, real-world barriers such as staffing shortages, infusion capacity constraints, and workflow demands can complicate the implementation of optimal care. This podcast series features expert-led conversations that deliver practical insights and real-world strategies to support confident, guideline-informed decision-making in the management of RRMM. Launch Date/Release: July 2, 2026 Expiration Date: August 31, 2027 FACULTY Ajai Chari, MD Professor of Clinical Medicine University of California, San Francisco Sagar Lonial, MD, FACP, FASCO Chair and Professor Department of Hematology and Medical Oncology Anne and Bernard Gray Family Chair in Cancer Chief Medical Officer Winship Caner Institute | Emory University This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link [https://www.practicepointcme.com/CMEHome/rrmm-podcasts-practical-insights-for-the-first-relapse] prior to listening to this podcast.

2 jul 20267 min
aflevering Episode 49 - Podcast: Bispecific Antibodies Across Targets: Practical Integration in RRMM - Part 3 of RRMM Podcasts: Practical Insights for the First Relapse artwork

Episode 49 - Podcast: Bispecific Antibodies Across Targets: Practical Integration in RRMM - Part 3 of RRMM Podcasts: Practical Insights for the First Relapse

Managing relapsed/refractory multiple myeloma (RRMM), particularly at first relapse, requires timely, evidence-based decisions in an increasingly complex treatment landscape. As therapeutic options continue to expand and clinical guidance evolves, healthcare professionals must navigate challenges related to risk stratification, treatment selection, sequencing strategies, and the integration of emerging immunotherapies into practice. Clinicians may also face uncertainty in distinguishing mechanisms of action, managing immune-related toxicities, and selecting appropriate therapies in the context of treatment resistance. Additionally, real-world barriers such as staffing shortages, infusion capacity constraints, and workflow demands can complicate the implementation of optimal care. This podcast series features expert-led conversations that deliver practical insights and real-world strategies to support confident, guideline-informed decision-making in the management of RRMM. Launch Date/Release: July 2, 2026 Expiration Date: August 31, 2027 FACULTY Ajai Chari, MD Professor of Clinical Medicine University of California, San Francisco Sagar Lonial, MD, FACP, FASCO Chair and Professor Department of Hematology and Medical Oncology Anne and Bernard Gray Family Chair in Cancer Chief Medical Officer Winship Caner Institute | Emory University This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link [https://www.practicepointcme.com/CMEHome/rrmm-podcasts-practical-insights-for-the-first-relapse] prior to listening to this podcast.

2 jul 202614 min
aflevering Episode 48 - Podcast: Making Sense of Immunotherapy Targets - Part 2 of RRMM Podcasts: Practical Insights for the First Relapse artwork

Episode 48 - Podcast: Making Sense of Immunotherapy Targets - Part 2 of RRMM Podcasts: Practical Insights for the First Relapse

Managing relapsed/refractory multiple myeloma (RRMM), particularly at first relapse, requires timely, evidence-based decisions in an increasingly complex treatment landscape. As therapeutic options continue to expand and clinical guidance evolves, healthcare professionals must navigate challenges related to risk stratification, treatment selection, sequencing strategies, and the integration of emerging immunotherapies into practice. Clinicians may also face uncertainty in distinguishing mechanisms of action, managing immune-related toxicities, and selecting appropriate therapies in the context of treatment resistance. Additionally, real-world barriers such as staffing shortages, infusion capacity constraints, and workflow demands can complicate the implementation of optimal care. This podcast series features expert-led conversations that deliver practical insights and real-world strategies to support confident, guideline-informed decision-making in the management of RRMM. Launch Date/Release: July 2, 2026 Expiration Date: August 31, 2027 FACULTY Ajai Chari, MD Professor of Clinical Medicine University of California, San Francisco Sagar Lonial, MD, FACP, FASCO Chair and Professor Department of Hematology and Medical Oncology Anne and Bernard Gray Family Chair in Cancer Chief Medical Officer Winship Caner Institute | Emory University This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link [https://www.practicepointcme.com/CMEHome/rrmm-podcasts-practical-insights-for-the-first-relapse] prior to listening to this podcast.

2 jul 202615 min
aflevering Episode 47 - Podcast: First Relapse Sets the Course - Part 1 of RRMM Podcasts: Practical Insights for the First Relapse artwork

Episode 47 - Podcast: First Relapse Sets the Course - Part 1 of RRMM Podcasts: Practical Insights for the First Relapse

Managing relapsed/refractory multiple myeloma (RRMM), particularly at first relapse, requires timely, evidence-based decisions in an increasingly complex treatment landscape. As therapeutic options continue to expand and clinical guidance evolves, healthcare professionals must navigate challenges related to risk stratification, treatment selection, sequencing strategies, and the integration of emerging immunotherapies into practice. Clinicians may also face uncertainty in distinguishing mechanisms of action, managing immune-related toxicities, and selecting appropriate therapies in the context of treatment resistance. Additionally, real-world barriers such as staffing shortages, infusion capacity constraints, and workflow demands can complicate the implementation of optimal care. This podcast series features expert-led conversations that deliver practical insights and real-world strategies to support confident, guideline-informed decision-making in the management of RRMM. Launch Date/Release: July 2, 2026 Expiration Date: August 31, 2027 FACULTY Ajai Chari, MD Professor of Clinical Medicine University of California, San Francisco Sagar Lonial, MD, FACP, FASCO Chair and Professor Department of Hematology and Medical Oncology Anne and Bernard Gray Family Chair in Cancer Chief Medical Officer Winship Caner Institute | Emory University This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link [https://www.practicepointcme.com/CMEHome/rrmm-podcasts-practical-insights-for-the-first-relapse] prior to listening to this podcast.

2 jul 202612 min